Q&A – Clinical trials
2cureX is happy to receive a number of questions and comments from our present and from potential future shareholders.
With the present Questions & Answers (Q&A) section, we would like to make these questions and their answers publicly available. Additional questions/comments should be mailed to info@2cureX.com.
Posted on 2020-10-04
It is expected that the final clinical data of the TICC1 trial will be published in Q1 2021. It is correct as the Principal Investigator Lars Henrik Jensen stated in the press release that the patients will go through a follow-up examination eight weeks after the IndiTreat-guided treatment is started. At the follow-up the effect of the treatment is evaluated by CT scanning. Thereafter data from all patients will need to be assembled, evaluated and published. We expect this finalized in the first quarter of 2021.
Posted on 2018-03-20
Yes, the first patients were enrolled end of October 2017. In February 2018 we had successfully enrolled the first 10 patients.
Please contact 2cureX for more information
September 15, 2021 at 15:00 (CET)
Interview with CEO Fernando Andreu (organized by Mangold) Open participation. Details provided later.
September 23, 2021
CSO Ole Thastrup will speak at the conference “Week of Health and Innovation 2021” in Odense, Denmark
September 28, 2021
Redeye Medtech & Diagnostics Investor meeting
September 29, 2021
Mangold Investor Lunch